

GlycoMimetics, Inc. Investor Relations Department 9708 Medical Center Drive Rockville, MD 20860 United States

Visit IR website ☐ Sign-up for email alerts ☐

13.41
4:00 PM ET 06/23/2017
1.31 🕇 (10.826%)
11.83 - 13.98
3.82 - 16.94
3,355,237

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

# **Company Profile**

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow's breakthrough treatments.

GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company's inception in 2003, we have developed a robust, diver... (more)

### **Stock Performance**



# Press Releases [View all]

### 06/12/2017

GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors

### 06/05/2017

GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference

### 06/05/2017

GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting

### 05/31/2017

GlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271

### 05/30/2017

GlycoMimetics Announces Closing of Public
Offering and Full Exercise of Underwriters'
Option to Purchase Additional Shares

## Financials [View all]

First Quarter Financial Results

03/01/2017

Annual Report (10-K)

04/20/2017

Proxy Statement (DEF 14A)

05/08/2017

Quarterly Report (10-Q)

11/04/2016

Quarterly Report (10-Q)

08/04/2016

Quarterly Report (10-Q)